Institution
Churchill Hospital
Healthcare•Oxford, United Kingdom•
About: Churchill Hospital is a healthcare organization based out in Oxford, United Kingdom. It is known for research contribution in the topics: Population & Transplantation. The organization has 3548 authors who have published 5357 publications receiving 304275 citations.
Topics: Population, Transplantation, Cancer, Diabetes mellitus, Type 2 diabetes
Papers published on a yearly basis
Papers
More filters
••
Partners HealthCare1, Stanford University2, Ohio State University3, National Institutes of Health4, University Medical Center Groningen5, GeneDx6, Harvard University7, University of Wisconsin-Madison8, Indiana University – Purdue University Indianapolis9, University of Virginia10, University of Oxford11, Churchill Hospital12, University of Sydney13, University of Amsterdam14
TL;DR: These adapted rules provide increased specificity for use in MYH7-associated disorders in combination with expert review and clinical judgment and serve as a stepping stone for genes and disorders with similar genetic and clinical characteristics.
256 citations
••
TL;DR: The issue of measuring ear and visual field advantages is discussed and some suggestions are made concerning the type of experimentation which may allow one to choose between the different laterality coefficients proposed in the literature.
256 citations
••
TL;DR: Evidence‐based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders and update and replace previous United Kingdom Haemophili Centre Doctors’ Organisation guidelines.
Abstract: Evidence-based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines.
254 citations
••
TL;DR: CQ does not reduce the durations of viraemia and NS1 antigenaemia in dengue patients and was associated with significantly more adverse events, primarily vomiting.
Abstract: Background
There is currently no licensed antiviral drug for treatment of dengue. Chloroquine (CQ) inhibits the replication of dengue virus (DENV) in vitro.
254 citations
••
Newcastle University1, University of Leeds2, Royal Melbourne Hospital3, University of Copenhagen4, University of Cape Town5, Princess Anne Hospital6, University of Birmingham7, University of Helsinki8, Karolinska Institutet9, St Mary's Hospital10, Belfast Health and Social Care Trust11, University of Hong Kong12, Leiden University13, Churchill Hospital14, John Hunter Hospital15, Western General Hospital16, Erasmus University Rotterdam17
TL;DR: The use of aspirin, resistant starch, or both for up to 4 years has no effect on the incidence of colorectal adenoma or carcinoma among carriers of the Lynch syndrome.
Abstract: Background Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant starch has been associated with an antineoplastic effect on the colon. Methods In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome. Results Among 1071 persons in 43 centers, 62 were ineligible to participate in the study, 72 did not enter the study, and 191 withdrew from the study. These three categories were equally distributed across the study groups. Over a mean period of 29 months (range, 7 to 74), colonic adenoma or carcinoma developed in 141 participants. Of 693 participants randomly assigned to receive aspirin or placebo, neoplasia developed in 66 participants receiving aspirin (18.9%), as compared with 65 receiving placebo (19.0%) (relative risk, 1.0; 95% confidence interval [CI], 0.7 to 1.4). There were no significant differences between the two groups with respect to the development of advanced neoplasia (7.4% and 9.9%, respectively; P = 0.33). Among the 727 participants receiving resistant starch or placebo, neoplasia developed in 67 participants receiving starch (18.7%), as compared with 68 receiving placebo (18.4%) (relative risk, 1.0; 95% CI, 0.7 to 1.4). Advanced adenomas and colorectal cancers were evenly distributed in the two groups. The prevalence of serious adverse events was low, and the events were evenly distributed.
254 citations
Authors
Showing all 3565 results
Name | H-index | Papers | Citations |
---|---|---|---|
Mark I. McCarthy | 200 | 1028 | 187898 |
Adrian L. Harris | 170 | 1084 | 120365 |
Nicholas J. White | 161 | 1352 | 104539 |
Andrew T. Hattersley | 146 | 768 | 106949 |
Paul Harrison | 133 | 1400 | 80539 |
John F. Thompson | 132 | 1420 | 95894 |
Thomas N. Williams | 132 | 1145 | 95109 |
Kevin Marsh | 128 | 567 | 55356 |
Mark Sullivan | 126 | 802 | 63916 |
Adrian V. S. Hill | 122 | 589 | 64613 |
Ian Tomlinson | 119 | 607 | 55576 |
Richard J.H. Smith | 118 | 1308 | 61779 |
Angela Vincent | 116 | 843 | 52784 |
Cecilia M. Lindgren | 115 | 368 | 89219 |
François Nosten | 114 | 777 | 50823 |